Development of a Genetically Stable Live Attenuated Influenza Vaccine Strain Using an Engineered High-Fidelity Viral Polymerase-Reference-Cited by-同舟云学术

Development of a Genetically Stable Live Attenuated Influenza Vaccine Strain Using an Engineered High-Fidelity Viral Polymerase

Published:2021-05-24 Issue:12 Volume:95 Page:
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

Mori Kotaro¹,Ohniwa Ryosuke L.²³,Takizawa Naoki⁴,Naito Tadasuke¹,Saito Mineki¹^ORCID

Affiliation:

1. Department of Microbiology, Kawasaki Medical School, Okayama, Japan

2. Division of Biomedical Science, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan

3. Center for Biotechnology, National Taiwan University, Taipei, Taiwan

4. Laboratory of Virology, Institute of Microbial Chemistry (BIKAKEN), Tokyo, Japan

Abstract

The LAIV currently in use is prescribed for actively immunizing individuals aged 2 to 49 years. However, it is not approved for infants and elderly individuals, who actually need it the most, because it might prolong virus propagation and cause an apparent infection in these individuals, due to their weak immune systems.

Funder

Kawasaki Medical School

MEXT | Japan Society for the Promotion of Science

Mochida Memorial Foundation for Medical and Pharmaceutical Research

Okayama Foundation for Science and Technology

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/JVI.00493-21

Reference57 articles.